About Translation initiation factor eIF2B subunit beta
Translation initiation factor eIF2B subunit beta (EIF2B2) is a protein
from Homo sapiens identified by UniProt accession
P49770, 351 residues long.
MolForge cross-references it against 0 known binders and
46 disease associations.
Target properties
| Protein name | Translation initiation factor eIF2B subunit beta |
| UniProt accession | P49770 |
| Gene | EIF2B2 |
| Organism | Homo sapiens |
| Length | 351 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (46)
Diseases linked to this target (Open Targets).
- leukoencephalopathy with vanishing white matter · score 0.67
- CACH syndrome · score 0.65
- ovarioleukodystrophy · score 0.60
- neurodegenerative disease · score 0.55
- leukoencephalopathy with vanishing white matter 1 · score 0.46
- Premature ovarian insufficiency · score 0.42
- congenital or early infantile CACH syndrome · score 0.37
- juvenile or adult CACH syndrome · score 0.37
- late infantile CACH syndrome · score 0.37
- osteogenesis imperfecta · score 0.34
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P49770-F1 | alphafold | PREDICTED | 86.54 | — |
Amino-acid sequence (351 residues)
MPGSAAKGSE LSERIESFVE TLKRGGGPRS SEEMARETLG LLRQIITDHR WSNAGELMEL IRREGRRMTA AQPSETTVGN MVRRVLKIIR EEYGRLHGRS DESDQQESLH KLLTSGGLNE DFSFHYAQLQ SNIIEAINEL LVELEGTMEN IAAQALEHIH SNEVIMTIGF SRTVEAFLKE AARKRKFHVI VAECAPFCQG HEMAVNLSKA GIETTVMTDA AIFAVMSRVN KVIIGTKTIL ANGALRAVTG THTLALAAKH HSTPLIVCAP MFKLSPQFPN EEDSFHKFVA PEEVLPFTEG DILEKVSVHC PVFDYVPPEL ITLFISNIGG NAPSYIYRLM SELYHPDDHV L
Explore Translation initiation factor eIF2B subunit beta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets